AstraZeneca (NASDAQ:AZN) and partner Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) on Saturday announced data from two late-stage trials to indicate how their blockbuster antitumor agent Enhertu could be effective in early breast cancer. The antibody-drug conjugate is currently indicated in the U.S. to ...